ICU Medical (ICUI) CFO Brian Bonnell Sells 9,307 Shares

What Happened

• Brian Michael Bonnell, Chief Financial Officer of ICU Medical, sold a total of 9,307 shares in open-market transactions on August 31, 2026, for aggregate proceeds of about $1,608,144.
• The sales were reported as four tranches: 1,712 shares at a weighted avg price of $171.05 ($292,843), 1,914 shares at $172.12 ($329,443), 4,568 shares at $173.44 ($792,291), and 1,113 shares at $173.91 ($193,567). Each tranche’s price is a weighted average of multiple executions (see footnotes for price ranges).
• These were sales (not purchases); sales by insiders are often routine (e.g., plan-based or for diversification/taxes) and do not by themselves indicate a change in company outlook.

Key Details

• Transaction date: 2026-08-31 (all four tranches).
• Prices (weighted averages) and ranges:
  • 1,712 sh @ $171.05 (range $170.57–$171.495) — F2
  • 1,914 sh @ $172.12 (range $171.625–$172.6) — F3
  • 4,568 sh @ $173.44 (range $172.69–$173.765) — F4
  • 1,113 sh @ $173.91 (range $173.77–$174.08) — F5
• Total shares sold: 9,307 for total proceeds ≈ $1,608,144.
• Shares owned after transaction: not specified in the information provided in this summary (refer to the full Form 4 for post-transaction holdings).
• Notable footnote: the sales were effected under a Rule 10b5-1 trading plan adopted June 1, 2026 (F1). The filing includes weighted-average prices and offers to provide per-price breakdowns on request.
• Filing timeliness: Form was filed with an accession date of 2026-08-31, the same date as the transactions — no late filing indicated in the provided data.

Context

• Trades executed under an established Rule 10b5-1 plan are prearranged and typically indicate planned disposition rather than ad hoc trading based on recent company developments. This is common for senior executives and helps avoid questions about timing.
• For retail investors, purchases tend to be more informative about insider sentiment; sales like these are common and can reflect routine portfolio management or tax planning rather than a negative signal. Refer to the full Form 4 for complete holdings and any additional disclosures.